Journal article

Lactobacillus GG treatment during pregnancy for the prevention of eczema: a randomized controlled trial

RJ Boyle, IH Ismail, S Kivivuori, PV Licciardi, RM Robins-Browne, L-J Mah, C Axelrad, S Moore, S Donath, JB Carlin, SJ Lahtinen, MLK Tang

ALLERGY | WILEY | Published : 2011


BACKGROUND: Probiotic supplementation in early life may be effective for preventing eczema. Previous studies have suggested that prenatal administration may be particularly important for beneficial effects. OBJECTIVE: We examined whether prenatal treatment with the probiotic Lactobacillus rhamnosus GG (LGG) can influence the risk of eczema during infancy. METHODS: We recruited 250 pregnant women carrying infants at high risk of allergic disease to a randomized controlled trial of probiotic supplementation (LGG 1.8 × 10(10) cfu/day) from 36 weeks gestation until delivery. Infants were assessed during their first year for eczema or allergic sensitization. Immunological investigations were perf..

View full abstract


Funding Acknowledgements

The studies were funded by grants from the Jack Brockhoff Foundation, the Murdoch Children's Research Institute, the Australian National Health and Medical Research Council and the Ilhan Food Allergy Foundation. Robert Boyle was supported by a University of Melbourne Baillieu Scholarship, a Murdoch Children's Research Institute Postgraduate Scholarship and a National Institute for Health Research Comprehensive Biomedical Research Centre. Intan Hakimah Ismail was supported by a scholarship from the Ministry of Higher Education, Malaysia and Universiti Putra Malaysia. Sampo Lahtinen was supported by Applied Biosciences Graduate School and Elintarvikkeiden Tutkimussaatio, Finland. LGG and placebo capsules were manufactured and supplied by Dicofarm ltd (Roma, Italy).